Study on hepato-protective mechanism of Ganlibao capsule based on network pharmacology

CHEN Jun; CHEN Qingshan; SUN Sen; ZHAO Liang; ZHANG Hai; ZHANG Guoqing

doi:10.3969/j.issn.1006-0111.2018.05.005

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To study the mechanism of Ganlibao capsule on liver protection by network pharmacology. Methods The active ingredients of Ganlibao capsule were selected and the targets of these ingredients were predicted by the reverse pharmacophore method. The molecule-regulatory network and protein-protein interaction network of the component-action target were constructed by Cytoscape and the String database respectively. The gene function and signal pathway analysis of the targets were analyzed by DAVID database. Results Nineteen active compounds were screened from the Ganlibao capsule, which involved 88 targets. The results of the network analysis showed that Ganlibao capsule exerted hepato-protective effects mainly through biological processes such as metabolic processes, regulation of cell death and response to lipids, and regulation of TNF, FoxO, Ras, ErbB, HIF-1, and TLR signaling pathways. Conclusion Ganlibao capsule could protect liver by multi-component, multi-target and multi-pathway, which might be through the regulation of cell death, TNF, FoxO, Ras and other related pathways.

Study on hepato-protective mechanism of Ganlibao capsule based on network pharmacology

1. Department of Pharmacy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

2. Department of Pharmacy, Shanghai First Maternal and Infant Hospital Affiliated to Tongji University, Shanghai 201204, China

Received Date: 2018-04-09

Rev Recd Date: 2018-06-25

Key words:

Abstract: Objective To study the mechanism of Ganlibao capsule on liver protection by network pharmacology. Methods The active ingredients of Ganlibao capsule were selected and the targets of these ingredients were predicted by the reverse pharmacophore method. The molecule-regulatory network and protein-protein interaction network of the component-action target were constructed by Cytoscape and the String database respectively. The gene function and signal pathway analysis of the targets were analyzed by DAVID database. Results Nineteen active compounds were screened from the Ganlibao capsule, which involved 88 targets. The results of the network analysis showed that Ganlibao capsule exerted hepato-protective effects mainly through biological processes such as metabolic processes, regulation of cell death and response to lipids, and regulation of TNF, FoxO, Ras, ErbB, HIF-1, and TLR signaling pathways. Conclusion Ganlibao capsule could protect liver by multi-component, multi-target and multi-pathway, which might be through the regulation of cell death, TNF, FoxO, Ras and other related pathways.

HTML

Reference (20)

[1]	王慧, 李洋, 周燕妮, 等. HPLC法同时测定肝力保胶囊中绿原酸及虎杖苷的含量[J]. 解放军药学学报,2015,31(4):338-340.
[2]	王慧, 路克军, 张国庆. 高效液相色谱法测定肝力保胶囊中苦参碱及槐定碱的含量[J]. 第二军医大学学报,2012,33(11):1267-1269.
[3]	李洋, 王慧, 吕磊,等. HPLC-TOF/MS对肝力保胶囊化学成分的快速鉴别[J]. 中国实验方剂学杂志,2015:70-73.
[4]	KIBBLE M, SAARINEN N, TANG J, et al. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products[J]. Nat Prod Rep,2015,32(8):1249-1266.
[5]	ZHAO S, IYENGAR R. Systems pharmacology:network analysis to identify multiscale mechanisms of drug action[J]. Annu Rev Pharmacol Toxicol,2012,52:505-521.
[6]	LI S, ZHANG B. Traditional Chinese medicine network pharmacology:theory, methodology and application[J]. Chin J Nat Med,2013,11(2):110-120.
[7]	李刚, 许波, 梁学振,等. 基于网络药理学研究淫羊藿抗骨质疏松的分子机制[J]. 中国药理学通报,2018(2):267-273.
[8]	冯燕燕, 谢媛媛, 汪艳平, 等. 基于"药物-靶点-通路"网络的血必净注射液治疗脓毒症分子调控机制[J]. 药学学报,2017,52(4):556-562.
[9]	王珂欣, 高丽, 周玉枝, 等. 基于网络药理学的苦参碱抗肝癌作用及机制研究[J]. 药学学报,2017,52(6):888-896.
[10]	蒋园, 白云, 刘萍, 等. 黄芪甲苷对CCl₄所致小鼠肝损伤的影响[J]. 中药药理与临床,2015,31(6):24-27.
[11]	张雅雯, 邵东燕, 师俊玲, 等. 山奈酚生物功能研究进展[J]. 生命科学,2017,29(4):400-405.
[12]	陈剑明, 张声生, 吴震宇, 等. 虎杖苷对非酒精性脂肪肝保护作用的实验研究[J]. 中华中医药学刊,2015,33(5):1188-1191+1294-1295.
[13]	战旗, 李悦悦, 王晓俊, 等. 人血白蛋白在原发性肝癌肝切除术后的应用分析[J]. 药学实践杂志,2015,33(5):463-466.
[14]	GARCIA-MARTINEZ R, CARACENI P, BERNARDI M, et al. Albumin:pathophysiologic basis of its role in the treatment of cirrhosis and its complications[J]. Hepatology,2013,58(5):1836-1846.
[15]	ZHAO G, HATTING M, NEVZOROVA YA,et al. Jnk1 in murine hepatic stellate cells is a crucial mediator of liver fibrogenesis[J]. Gut,2014,63(7):1159-1172.
[16]	POLIVKA J Jr,JANKU F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J]. Pharmacol Ther,2014,142(2):164-175.
[17]	BRENNER C, GALLUZZI L, KEPP O, et al. Decoding cell death signals in liver inflammation[J]. J Hepatol,2013,59(3):583-594.
[18]	PAN X, ZHANG Y, KIM HG, et al. FOXO transcription factors protect against the diet-induced fatty liver disease[J]. Sci Rep,2017,7:44597.
[19]	DOWNWARD J. Targeting RAS signalling pathways in cancer therapy[J]. Nat Rev Cancer,2003,3(1):11-22.
[20]	SEKI E, PARK E, FUJIMOTO J. Toll-like receptor signaling in liver regeneration, fibrosis and carcinogenesis[J]. Hepatol Res,2011,41(7):597-610.

Message Board

Study on hepato-protective mechanism of Ganlibao capsule based on network pharmacology

doi: 10.3969/j.issn.1006-0111.2018.05.005

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views